Stockhouse.com uses cookies on this site. By continuing to use our service, you agree to our use of cookies. Cookies are used to offer you a better browsing experience and to analyze our traffic. We also use them to share usage information with our partners. See full details.
I Agree
×
Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Privacy Policy | Disclaimer

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Privacy Policy | Disclaimer
Please Try Again {{ error }}

Send my password

Return to Login
SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
News Focus
TRILLION ENERGY ANNOUNCES SUCCESSFUL SASB GAS PERFORATIONS (click to learn more)
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Breaking & Recent News Mallinckrodt PLC MNKTQ

Healthcare
Mallinckrodt plc develops, manufactures, markets and distributes branded and generic specialty pharmaceutical products and therapies. The Company focuses on various therapeutic areas, such as autoimmune and rare disease specialty areas, including neurology, rheumatology, nephrology, ophthalmology and pulmonology; immunotherapy and neonatal critical care respiratory therapies; analgesics and... see more

Recent & Breaking News (OTCPK:MNKTQ)

Mallinckrodt Presents Data on TERLIVAZ® (terlipressin) for Injection in Patients with Hepatorenal Syndrome (HRS) at the 2024 European Association for the Study of the Liver (EASL) Congress

PR Newswire June 5, 2024

Mallinckrodt plc Reports First Quarter 2024 Financial Results and Reaffirms Full Year Guidance

PR Newswire May 9, 2024

Mallinckrodt Announces Journal Publication of Real-World Data on Acthar® Gel (repository corticotropin injection) to Treat Symptomatic Sarcoidosis in African American and Non-African American Patients

PR Newswire March 11, 2024

Mallinckrodt Announces Board of Directors and Leadership Updates

PR Newswire February 2, 2024

Mallinckrodt Presents New Data on TERLIVAZ® (terlipressin) for Injection at the Society of Critical Care Medicine (SCCM) 2024 Critical Care Congress

PR Newswire January 22, 2024

Mallinckrodt Completes Financial Restructuring and Irish Examinership Proceedings and Emerges From Chapter 11

PR Newswire November 14, 2023

High Court of Ireland Confirms Mallinckrodt Scheme of Arrangement

PR Newswire November 10, 2023

Mallinckrodt to Present Breadth of Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Association for the Study of Liver Diseases (AASLD) 2023 Liver Meeting

PR Newswire November 8, 2023

Mallinckrodt plc (in Examinership) Reports Third Quarter 2023 Financial Results

PR Newswire November 7, 2023

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American Society of Nephrology (ASN) Kidney Week 2023 Scientific Meeting

PR Newswire November 1, 2023

Mallinckrodt Presents Latest Health Economics Data on Acthar® Gel (Repository Corticotropin Injection) at the Academy of Managed Care Pharmacy (AMCP) Nexus 2023

PR Newswire October 26, 2023

Mallinckrodt to Present Data on TERLIVAZ® (terlipressin) for Injection in Adult Patients with Hepatorenal Syndrome (HRS) at the American College of Gastroenterology (ACG) Annual Scientific Meeting

PR Newswire October 22, 2023

Mallinckrodt plc (in examinership) Receives U.S. Court Approval for Financial Restructuring Plan

PR Newswire October 10, 2023

Mallinckrodt Announces Publication of Two Journal Manuscripts with Clinical and Economic Evidence for Acthar® Gel (Repository Corticotropin Injection)

PR Newswire October 10, 2023

Mallinckrodt Deadline Alert

Newsfile September 5, 2023

Mallinckrodt Deadline Alert

Newsfile September 4, 2023

Mallinckrodt Shareholder Notice

Newsfile September 3, 2023

MALLINCKRODT DEADLINE ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $100,000 In Mallinckrodt To Contact Him Directly To Discuss Their Options

PR Newswire September 2, 2023

Mallinckrodt Shareholder Notice

Newsfile September 1, 2023

The Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Mallinckrodt plc (MNK)

Business Wire September 1, 2023